Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-02-07 23:57 | 2014-02-05 | N/A | N/A | Centerbridge Credit Partners, L.P. | 10% owner, Other | Other | BUY | $117.50 | 12,000 | $1,410,000 | 1,202,892 | +1.0% |
| 2014-02-07 19:57 | 2014-02-05 | TRVN | Trevena, Inc. | Alta Partners VIII, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $7.00 | 472,410 | $3,306,870 | 3,890,262 | +13.8% |
| 2014-02-07 20:06 | 2014-02-05 | TRVN | Trevena, Inc. | Polaris Venture Management Co. V, L.L.C. | 10% owner | Pharmaceutical Preparations | BUY | $7.00 | 472,405 | $3,306,835 | 3,811,682 | +14.1% |
| 2014-02-07 20:02 | 2014-02-05 | TRVN | Trevena, Inc. | HealthCare Ventures VIII, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $7.00 | 297,058 | $2,079,406 | 2,446,251 | +13.8% |
| 2014-02-07 20:16 | 2014-02-05 | TRVN | Trevena, Inc. | New Enterprise Associates 12, Limited Partnership | 10% owner | Pharmaceutical Preparations | BUY | $7.00 | 472,410 | $3,306,870 | 3,811,691 | +14.1% |
| 2014-02-06 14:47 | 2014-02-05 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner - CEO & Chairman | Pharmaceutical Preparations | BUY | $7.59 | 349,740 | $2,655,926 | 139,175,659 | +0.3% |
| 2014-02-06 14:46 | 2014-02-05 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner - CEO & Chairman | Pharmaceutical Preparations | BUY | $7.45 | 150,260 | $1,119,692 | 138,825,919 | +0.1% |
| 2014-02-07 00:18 | 2014-02-05 | RGDO | N/A | KIERLIN ROBERT A | 10% owner | Other | BUY | $5.00 | 400,000 | $2,000,000 | 3,700,955 | +12.1% |
| 2014-02-06 23:53 | 2014-02-04 | CLDN | N/A | PFIZER INC | 10% owner | Other | BUY | $8.00 | 227,261 | $1,818,088 | 1,794,803 | +14.5% |
| 2014-02-06 23:47 | 2014-02-04 | CLDN | N/A | Lundbeckfond Invest A/S | 10% owner | Other | BUY | $8.00 | 182,681 | $1,461,448 | 1,745,683 | +11.7% |
| 2014-02-06 23:44 | 2014-02-04 | CLDN | N/A | Kordel Johan | Director | Other | BUY | $8.00 | 182,681 | $1,461,448 | 1,745,683 | +11.7% |
| 2014-02-06 23:43 | 2014-02-04 | CLDN | N/A | Funder Joshua | Director | Other | BUY | $8.00 | 227,261 | $1,818,088 | 1,194,204 | +23.5% |
| 2014-02-06 23:41 | 2014-02-04 | CLDN | N/A | Enterprise Partners Management LLC | 10% owner | Other | BUY | $8.00 | 133,083 | $1,064,664 | 1,950,184 | +7.3% |
| 2014-02-06 23:52 | 2014-02-04 | CLDN | N/A | Novartis Bioventures Ltd | 10% owner | Other | BUY | $8.00 | 162,386 | $1,299,088 | 1,551,721 | +11.7% |
| 2014-02-07 03:30 | 2014-02-04 | REGN | REGENERON PHARMACEUTICALS, INC. | Sanofi | 10% owner | Pharmaceutical Preparations | BUY | $284.12 | 397,264 | $112,871,879 | 16,581,109 | +2.5% |
| 2014-02-07 01:26 | 2014-02-04 | AON | Aon plc | KNIGHT LESTER B | Director | Insurance Agents, Brokers & Service | BUY | $77.31 | 30,000 | $2,319,150 | 30,000 | +100.0% |
| 2014-02-06 02:59 | 2014-01-31 | RARE | Ultragenyx Pharmaceutical Inc. | FMR LLC | 10% owner, Other | Pharmaceutical Preparations | BUY | $21.00 | 175,000 | $3,675,000 | 3,260,240 | +5.7% |
| 2014-02-06 01:30 | 2014-02-04 | DRNA | N/A | RA CAPITAL MANAGEMENT, LLC | 10% owner, Other | Other | BUY | $15.00 | 1,000,000 | $15,000,000 | 2,428,571 | +70.0% |
| 2014-02-06 02:29 | 2014-02-04 | DRNA | N/A | Skyline Venture Partners V LP | 10% owner | Other | BUY | $15.00 | 200,000 | $3,000,000 | 1,734,751 | +13.0% |
| 2014-02-06 01:17 | 2014-02-05 | CARA | Tvardi Therapeutics, Inc. | VOGELBAUM MARTIN | Director | Pharmaceutical Preparations | BUY | $11.00 | 225,818 | $2,483,998 | 2,668,057 | +9.2% |
| 2014-02-06 00:54 | 2014-02-05 | CARA | Tvardi Therapeutics, Inc. | ALTA BIOPHARMA PARTNERS III LP | 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 112,817 | $1,240,987 | 43,212 | +100.0% |
| 2014-02-06 02:21 | 2014-02-04 | DRNA | N/A | HOFFMAN STEPHEN J | Director, 10% owner | Other | BUY | $15.00 | 200,000 | $3,000,000 | 1,734,751 | +13.0% |
| 2014-02-05 23:38 | 2014-02-04 | RGLS | N/A | Sanofi | 10% owner | Other | BUY | $7.67 | 1,303,780 | $9,999,993 | 5,053,779 | +34.8% |
| 2014-02-06 01:14 | 2014-02-05 | CARA | Tvardi Therapeutics, Inc. | RHO Ventures VI LP | 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 225,818 | $2,483,998 | 2,668,057 | +9.2% |
| 2014-02-06 03:33 | 2014-02-03 | WSTC | N/A | WEST GARY L | 10% owner | Other | BUY | $21.97 | 113,247 | $2,488,252 | 113,247 | +100.0% |
| 2014-02-06 03:29 | 2014-02-03 | WSTC | N/A | WEST MARY E | 10% owner | Other | BUY | $21.97 | 113,247 | $2,488,252 | 113,247 | +100.0% |
| 2014-02-04 19:24 | 2014-02-04 | ABIO | Oruka Therapeutics, Inc. | mccormack riley | 10% owner | Pharmaceutical Preparations | BUY | $1.70 | 1,000,000 | $1,700,000 | 3,000,000 | +50.0% |
| 2014-02-05 00:05 | 2014-01-31 | YRCW | N/A | Carlyle Group Management L.L.C. | 10% owner | Other | BUY | $15.00 | 2,333,333 | $34,999,995 | 4,083,122 | +133.3% |
| 2014-02-05 00:06 | 2014-01-31 | YRCW | N/A | TC Group CSP II, LLC | 10% owner | Other | BUY | $15.00 | 2,333,333 | $34,999,995 | 4,083,122 | +133.3% |
| 2014-02-05 00:54 | 2013-07-02 | PETX | N/A | Lichter Jay | Director, 10% owner | Other | BUY | $6.00 | 500,000 | $3,000,000 | 4,170,543 | +13.6% |
| 2014-02-04 21:11 | 2014-02-03 | KCG | N/A | Coleman Daniel | Director, Officer - Chief Executive Officer | Other | BUY | $11.04 | 805,000 | $8,890,662 | 1,274,878 | +171.3% |
| 2014-02-04 20:31 | 2014-01-31 | PSX | Phillips 66 | Loomis William R Jr | Director | Petroleum Refining | BUY | $73.55 | 13,600 | $1,000,277 | 21,360 | +175.3% |
| 2014-02-05 01:36 | 2014-01-31 | YRCW | N/A | LASRY MARC | 10% owner | Other | BUY | $15.00 | 4,133,333 | $61,999,995 | 854,675 | +100.0% |
| 2014-02-04 21:10 | 2014-02-03 | KCG | N/A | HALDEMAN CHARLES E | Director | Other | BUY | $11.04 | 100,000 | $1,104,430 | 152,972 | +188.8% |
| 2014-02-04 20:23 | 2014-02-03 | CRTX | N/A | Chiesi Farmaceutici SpA | 10% owner | Other | BUY | $9.50 | 11,542,313 | $109,651,974 | 10,000 | +100.0% |
| 2014-02-05 03:11 | 2014-01-31 | REGN | REGENERON PHARMACEUTICALS, INC. | Sanofi | 10% owner | Pharmaceutical Preparations | BUY | $283.78 | 208,972 | $59,303,098 | 16,183,845 | +1.3% |
| 2014-02-05 00:25 | 2014-01-31 | IDIX | N/A | BAUPOST GROUP LLC/MA | 10% owner | Other | BUY | $6.50 | 16,420,241 | $106,731,567 | 53,331,109 | +44.5% |
| 2014-02-05 04:19 | 2014-02-04 | DRNA | N/A | Flynn James E | 10% owner, Other | Other | BUY | $15.00 | 1,000,000 | $15,000,000 | 972,642 | +100.0% |
| 2014-02-04 00:21 | 2014-01-30 | JPM | JPMORGAN CHASE & CO | CROWN JAMES S | Director | National Commercial Banks | BUY | $55.53 | 500,000 | $27,762,600 | 18,803 | +100.0% |
| 2014-01-31 20:07 | 2013-12-13 | KMP | N/A | Wuerth James P | Officer - Vice President (President CO2) | Other | BUY | $79.08 | 20,000 | $1,581,544 | 20,000 | +100.0% |
| 2014-01-31 23:17 | 2014-01-29 | LIQD | N/A | VON ALLMEN DOUGLAS J | 10% owner | Other | BUY | $5.50 | 559,891 | $3,079,401 | 110,258 | +100.0% |
| 2014-02-01 00:12 | 2014-01-29 | RGS | REGIS CORP | Beltzman Daniel Gordon | Director, 10% owner | Services-Personal Services | BUY | $12.16 | 1,502,507 | $18,264,776 | 1,361,044 | +100.0% |
| 2014-02-01 02:40 | 2014-01-29 | VTSS | N/A | MARTIN WILLIAM C | 10% owner | Other | BUY | $3.44 | 2,038,000 | $7,016,630 | 12,429,127 | +19.6% |
| 2014-01-30 19:24 | 2014-01-21 | N/A | N/A | Centerbridge Credit Partners, L.P. | 10% owner, Other | Other | BUY | $120.50 | 144,000 | $17,352,000 | 1,090,892 | +15.2% |
| 2014-01-31 03:46 | 2014-01-29 | RICE | N/A | CHRISTMAS JAMES W | Director | Other | BUY | $21.00 | 175,000 | $3,675,000 | 25,000 | +100.0% |
| 2014-01-31 01:42 | 2014-01-29 | IRT | INDEPENDENCE REALTY TRUST, INC. | RAIT Financial Trust | 10% owner | Real Estate Investment Trusts | BUY | $8.30 | 1,204,819 | $9,999,998 | 6,969,719 | +20.9% |
| 2014-01-30 01:18 | 2014-01-28 | XLRN | N/A | CELGENE CORP /DE/ | 10% owner | Other | BUY | $50.00 | 300,000 | $15,000,000 | 3,472,887 | +9.5% |
| 2014-01-29 16:20 | 2014-01-27 | REGN | REGENERON PHARMACEUTICALS, INC. | Sanofi | 10% owner | Pharmaceutical Preparations | BUY | $275.90 | 157,920 | $43,570,365 | 15,974,873 | +1.0% |
| 2014-01-29 00:33 | 2014-01-24 | N/A | N/A | Centerbridge Credit Partners, L.P. | 10% owner, Other | Other | BUY | $119.25 | 100,000 | $11,925,000 | 1,190,892 | +9.2% |
| 2014-01-28 16:48 | 2014-01-27 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner - CEO & Chairman | Pharmaceutical Preparations | BUY | $8.22 | 177,722 | $1,460,324 | 138,539,259 | +0.1% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.